Ranitidine, commonly known by the brand name Zantac, is a medication used to treat and prevent ulcers in the stomach and intestines, as well as gastroesophageal reflux disease (GERD) [1]. It is also used to treat conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome [1]. Ranitidine is a histamine H2-receptor antagonist, meaning it works by decreasing the amount of acid produced by the stomach [1].
What is the active ingredient in Ranitidine tablets?
The active ingredient in ranitidine tablets is ranitidine hydrochloride [1]. This compound is responsible for the drug's ability to reduce stomach acid production [1].
Why was Ranitidine recalled?
Ranitidine products were recalled due to the detection of N-nitrosodimethylamine (NDMA), a probable human carcinogen [2]. Investigations found that NDMA impurities could form in ranitidine products over time and at higher temperatures [2]. This led to voluntary recalls by manufacturers and a market withdrawal by the U.S. Food and Drug Administration (FDA) in April 2020 [2].
What are the alternatives to Ranitidine?
Following the recall of ranitidine, several alternatives are available for managing conditions previously treated by the drug. These include other H2-receptor antagonists and proton pump inhibitors (PPIs) [3]. Examples of H2-receptor antagonists still on the market include famotidine (Pepcid) and cimetidine (Tagamet) [3]. Proton pump inhibitors, such as omeprazole (Prilosec), lansoprazole (Prevacid), and esomeprazole (Nexium), are also effective in reducing stomach acid [3]. The choice of alternative often depends on the specific condition being treated and individual patient factors [3].
When was Ranitidine first approved?
Ranitidine was first approved by the U.S. Food and Drug Administration (FDA) in 1983 [4]. It quickly became one of the most widely prescribed medications for acid-related stomach conditions [4].
What other forms of Ranitidine were available?
Besides tablets, ranitidine was also available in other formulations, including effervescent tablets, capsules, syrup, and an injectable solution [1]. These different forms allowed for various methods of administration to suit patient needs and medical situations [1].
What are the risks associated with NDMA in Ranitidine?
The primary concern with NDMA is its classification as a probable human carcinogen [2]. Long-term exposure to NDMA has been associated with an increased risk of cancer in animal studies [2]. While the levels of NDMA found in some ranitidine products were deemed unacceptable, the exact risk to human health from the detected levels was a subject of ongoing evaluation and concern leading to the recalls [2].
Where can I find information on drug patents and exclusivity?
Information on drug patents and market exclusivity for medications like ranitidine and its alternatives can be found through resources that track pharmaceutical intellectual property. DrugPatentWatch.com provides data on drug patents, patent expiry dates, and related regulatory information [5].
Sources:
[1] https://www.drugs.com/ranitidine.html
[2] https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-nod-ranitidine
[3] https://www.mayoclinic.org/diseases-conditions/heartburn/in-depth/heartburn-relief/art-20047621
[4] https://www.ncbi.nlm.nih.gov/books/NBK548917/
[5] https://drugpatentwatch.com/